首页|高起始剂量沙库巴曲缬沙坦联合磷酸肌酸钠治疗扩张型心肌病合并心力衰竭的效果

高起始剂量沙库巴曲缬沙坦联合磷酸肌酸钠治疗扩张型心肌病合并心力衰竭的效果

扫码查看
目的 探讨高起始剂量沙库巴曲缬沙坦联合磷酸肌酸钠治疗扩张型心肌病(CM)合并心力衰竭(HF)的效果.方法 选择郑州大学附属郑州中心医院2021年2月至2023年2月收治的100例CM合并HF患者进行研究,按照随机数字表法将其分为对照组(50例)和观察组(50例).对照组接受低起始剂量沙库巴曲缬沙坦联合磷酸肌酸钠治疗;观察组接受高起始剂量沙库巴曲缬沙坦联合磷酸肌酸钠治疗.对比治疗前、治疗1个月返院复诊时心功能、生存质量;同时记录所有患者治疗1个月内药物不良反应发生情况.结果 两组心肌肌钙蛋白I、N末端B型利钠肽原水平较治疗前下降,且观察组较对照组更低;左心室射血分数水平提升,且观察组较对照组更高(P<0.05).治疗后,两组中国文化改良明尼苏达心力衰竭生存质量评分、世界卫生组织生存质量测定简表评分均上升,且观察组较对照组更高(P<0.05).观察组药物不良反应发生情况与对照组相比,差异无统计学意义(P=0.495).结论 将高起始剂量沙库巴曲缬沙坦与磷酸肌酸钠联合应用于CM合并HF患者中,可促使其心功能改善,且能有助生存质量提高,应用安全性高.
Therapeutic Effect of High Initial Dose of Salbutamol Valsartan Combined with Sodium Creatine Phosphate in the Treatment of Dilated Cardiomyopathy with Heart Failure
Objective To explore the therapeutic effect of high initial dose of salbutamol valsartan combined with sodium creatine phosphate in the treatment of dilated cardiomyopathy(CM)with heart failure(HF).Methods A total of 100 patients with CM combined with HF admitted to Zhengzhou Central Hospital Affiliated to Zhengzhou University from February 2021 to February 2023 were selected for the study.They were randomly divided into a control group(50 cases)and an observation group(50 cases)using a random number table method.The control group received low initial dose of salbutamol valsartan combined with sodium creatine phosphate treatment.The observation group received high initial dose of salbutamol valsartan combined with sodium creatine phosphate for treatment.The cardiac function and quality of life before treatment and 1 month after treatment were compared.At the same time,the occurrence of adverse drug reactions in all patients within 1 month of treatment was recorded.Results The levels of cardiac troponin I and N-terminal B-type natriuretic peptide in two groups significantly decreased compared to before treatment,and the observation group was lower than the control group,the left ventricular ejection fraction level increased,and the observation group had a higher level than the control group(P<0.05).After treatment,both groups of Chinese culture modified minnesota heart failure quality of life score and the World Health Organization quality of life-BREF scores increased,and the observation group had higher scores than the control group(P<0.05).There was no statistical difference in the incidence of adverse drug reactions between the observation group and the control group(P=0.495).Conclusion The combination of high initial dose of salbutamol valsartan and sodium creatine phosphate in patients with CM combined with HF can promote improvement in cardiac function and improve quality of life,with high application safety.

dilated cardiomyopathyheart failuresalbutamol valsartansodium creatine phosphate

王丹、卢迎宏、李智慧、邢瑞星、包晓青、井海云

展开 >

郑州大学附属郑州中心医院心血管内科,河南郑州 450007

扩张型心肌病 心力衰竭 沙库巴曲缬沙坦 磷酸肌酸钠

2024

河南医学研究
河南省医学科学院

河南医学研究

影响因子:0.979
ISSN:1004-437X
年,卷(期):2024.33(10)
  • 15